Patients with peripheral artery disease (PAD) are at heightened risk for ischemic events
related to atherothrombosis. Antithrombotic therapies can reduce the risk of …

Peripheral artery disease affects> 200 million people worldwide and is associated with
significant limb and cardiovascular morbidity and mortality. Limb revascularization is …

Peripheral artery disease (PAD) affects over 200 million people globally and is a cause of
significant morbidity, mortality, and disability due to limb loss. Although secondary …

Patients with peripheral artery disease (PAD) are at an increased risk of major adverse
cardiovascular events, and those with disease in the lower extremities are at risk of major …

Peripheral artery disease (PAD) is a morbid and costly disease that can result in loss of limb
and life if not managed appropriately with risk factor modification, antithrombotic therapy …

Atherosclerotic cardiovascular (CV) disease remains a major health concern affecting more
than 200 million adults worldwide, and lower extremity peripheral artery disease (PAD) is …

We reviewed the various antithrombotic therapies available to treat peripheral artery disease
(PAD). A literature review using the PubMed and MEDLINE databases used the following …

Cardioprotective medications and risk-factor modification are the hallmarks of treatment for
all patients with peripheral artery disease (PAD). If symptoms are life-limiting and/or do not …

Antiplatelet agents are recommended for the reduction of major adverse cardiovascular
events among all patients with symptomatic peripheral artery disease. However, the optimal …

Peripheral arterial disease (PAD) is well recognized as a marker for systemic
atherosclerosis. Platelets play an essential role in all stages of the disease, contributing to …